News

Home>News
News2020-07-17T11:41:26-04:00
Sep 82020

Halberd Corporation Research on Covid-19 Treatment Development Begins at ASU

September 8th, 2020|Categories: Featured, Investor News, News|Tags: , , , , , , |

Jackson Center, PA, September 8, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced Arizona State University (ASU) commenced its research work for Halberd Corp. The initial phases of ASU’s research focuses on the development of antibodies in support of Halberd’s two issued patents and three Covid-19 related provisional patent applications for extracorporeal removal of the virus’ antigens from a patient’s blood.  Those antibodies could be multifaceted, including with regard to other viruses. The research ...

Sep 22020

Why Halberd Corporation Selected ASU And Where They Stand Among Other Universities

September 2nd, 2020|Categories: Featured, Investor News, News|Tags: , , , , , |

Jackson Center, PA, September 2, 2020 – Halberd Corporation (OTC PINK: "HALB") today revealed why they selected Arizona State University (ASU) to conduct sponsored research to develop a Covid-19 treatment. ASU is one of the fastest growing research universities in the country and ranks among the top 10 for Department of Health and Human Services funding among all U.S. institutions without a medical school, placing them ahead of Princeton, Georgia Tech and Carnegie Mellon University.  ...

Aug 312020

Halberd Selects Arizona State University (ASU) to Develop Its Patented Covid-19 Treatment(s)

August 31st, 2020|Categories: Featured, Investor News, News|Tags: , , , , , , |

Jackson Center, PA, August 31, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced the signing of a development agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments.  The work will focus on developing antibodies in support of Halberd’s two issued patents and three Covid-19 related provisional patent applications for extracorporeal removal of the virus’ antigens from a patient’s blood. It will also focus on neutralizing the effects of ...

Aug 272020

Halberd Corporation Selects University Research Partner

August 27th, 2020|Categories: Featured, News, Technology|Tags: , , , |

Jackson Center, PA, August 27, 2020 – Halberd Corp. (OTC PINK: "HALB") is pleased to announce the successful completion of its search for a major research university partner. The University, to be announced, is engaged to develop compounds for use in Halberd’s patented extracorporeal treatment of Covid-19.  Terms of the agreement have been finalized and signatures on the contract reflecting the agreed terms, is in process. Details will be released shortly. For more information please ...

Aug 182020

Halberd Corporation CEO Answers Shareholders’ Questions Regarding Covid-19 Treatment

August 18th, 2020|Categories: Featured, Investor News, News, Technology|

Jackson Center, PA, August 18, 2020 – Halberd Corp. (OTC PINK: "HALB") Chairman, President & CEO of Halberd Corporation, William A. Hartman, has received a number of questions from shareholders regarding the extracorporeal process for treatment of Covid-19. Below, Mr. Hartman responds to those questions. Q:  There are various extracorporeal medical procedures being researched or used and in various states of trial and approval.  How do these differ from your patented process? A:  All extracorporeal ...

Go to Top